Markus Goebel

Director/Board Member at OSE IMMUNOTHERAPEUTICS

Health Technology

Consumer Services

Retail Trade

Profile

Markus Goebel has held various director positions in multiple pharmaceutical and biotech companies.
He is currently a Director at FoldRx.
Pharmaceuticals LLC, Sorbent Therapeutics, Inc., EraGen Biosciences, Inc., Merganser Biotech, Inc., and OSE Immunotherapeutics SA. In the past, he has also served as a Director at Sirtris Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Zikani Therapeutics, Inc., Locus Pharmaceuticals, Inc., LigoCyte Pharmaceuticals, Inc., Intellikine LLC, Novartis Services, Inc., Novartis Venture Funds (USA), eFFECTOR Therapeutics Operations, Inc., and ESCAPE Bio, Inc. Dr. Goebel holds an MBA from Henley Management College and a doctorate from Ludwig-Maximilians-Universität München.

Markus Goebel active positions

Companies	Position	Start
OSE IMMUNOTHERAPEUTICS	Director/Board Member	19/06/2024
Merganser Biotech, Inc. Merganser Biotech, Inc. BiotechnologyHealth Technology Provides biotechnology services	Director/Board Member	-
FoldRx Pharmaceuticals LLC FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services	Director/Board Member	-
EraGen Biosciences, Inc. EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets molecular diagnostic testing products	Director/Board Member	01/01/2004
Sorbent Therapeutics, Inc. Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases	Director/Board Member	-

All active positions of Markus Goebel

Former positions of Markus Goebel

Companies	Position	End
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Private Equity Investor	30/04/2019
LigoCyte Pharmaceuticals, Inc. LigoCyte Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Developed vaccines and monoclonal antibody therapeutics	Director/Board Member	16/04/2014
Locus Pharmaceuticals, Inc. Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services	Director/Board Member	-
Novartis Services, Inc. Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company	President	29/01/2010
░░░░░░░░░░░ ░░░	░░░░░░░░░░░░░░ ░░░░░░	-

See the detail of Markus Goebel's experience

Training of Markus Goebel

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Markus Goebel's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	17
FoldRx Pharmaceuticals LLC FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services	Health Technology
Sirtris Pharmaceuticals, Inc. Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs and pharmaceuticals	Health Technology
Sorbent Therapeutics, Inc. Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases	Health Technology
Ra Pharmaceuticals, Inc. Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease	Health Technology
Zikani Therapeutics, Inc. Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens	Retail Trade
Locus Pharmaceuticals, Inc. Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services	Health Technology
EraGen Biosciences, Inc. EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets molecular diagnostic testing products	Health Technology
Henley Management College Henley Management College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Ludwig-Maximilians-Universität München Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
LigoCyte Pharmaceuticals, Inc. LigoCyte Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Developed vaccines and monoclonal antibody therapeutics	Health Technology
Intellikine LLC Intellikine LLC Pharmaceuticals: MajorHealth Technology Develops and manufactures small molecule drugs for the treatment of cancer	Health Technology
Novartis Services, Inc. Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company	Health Technology
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Finance
eFFECTOR Therapeutics Operations, Inc. eFFECTOR Therapeutics Operations, Inc. BiotechnologyHealth Technology Operates a clinical-stage biopharmaceutical company that develops oncology drugs	Health Technology
Merganser Biotech, Inc. Merganser Biotech, Inc. BiotechnologyHealth Technology Provides biotechnology services	Health Technology
OSE Immunotherapeutics SA OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers	Health Technology
ESCAPE Bio, Inc. ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease	Health Technology